Treatment Planning for Molecular Targeted Radionuclide Therapy-Reference-Cited by-同舟云学术

Treatment Planning for Molecular Targeted Radionuclide Therapy

Published:2002-06 Issue:3 Volume:17 Page:267-280
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Hartmann Siantar Christine L.¹,Vetter Kai¹,DeNardo Gerald L.²,DeNardo Sally J.²

Affiliation:

1. Glenn T. Seaborg Institute, Lawrence Livermore National Laboratory, Livermore, California

2. Radiodiagnosis and Therapy, Division of Hematology/Oncology, University of California Davis Medical Center, Sacramento, California

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/10849780260179233

Reference57 articles.

1. A new era for radiolabeled antibodies in cancer?

2. DOSE, TIME, VOLUME RELATIONSHIPS IN SQUAMOUS CELL CARCINOMA OF THE SUPRAGLOTTIC LARYNX

3. Clinical dose-response curves of human malignant epithelial tumours

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the accuracy of mono-energetic electron and beta-emitting isotope dose-point kernels using particle and heavy ion transport code system: PHITS;Applied Radiation and Isotopes;2017-10

2. Time-integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: A simulation study on the effect of sampling schedule and noise;Medical Physics;2016-08-19

3. Treatment planning in molecular radiotherapy;Zeitschrift für Medizinische Physik;2013-12

4. Radioiodine Therapy for Graves Disease;Clinical Nuclear Medicine;2013-04

5. Determining thyroid 131 I effective half-life for the treatment planning of Graves’ disease;Medical Physics;2013-02-01